PRAMEF5

Across TCGA pan-cancer cohorts, PRAMEF5 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated PRAMEF5 data layer compared with 1 for mutation status.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PRAMEF5 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF5 expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.

KIRC, LUAD, and THCA are the cancer types where PRAMEF5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	II,III,IV	0.167	0.760	<.001	54	view →
LUAD	OS	Tertile	II,III,IV	0.111	0.750	<.001	54	view →
THCA	OS	Tertile	All	0.240	0.931	.003	48	view →
STAD	DFS	Tertile	All	0.464	0.728	.004	36	view →
GBM	OS	Tertile	All	0.005	0.416	<.001	36	view →
LGG	OS	Tertile	All	0.460	0.837	<.001	30	view →
BLCA	DFS	Tertile	III,IV	0.094	0.489	.005	27	view →
THYM	DFS	Tertile	III,IV	0.205	0.772	.032	9	view →
CHOL	OS	Tertile	All	0.155	0.725	.029	9	view →
LIHC	DFS	Tertile	II,III,IV	0.938	0.410	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PRAMEF5–KIRC (DFS)

Open the KIRC breakdown →